Submitted:
30 April 2024
Posted:
01 May 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Patients and Methods
2.1. Study Participants
2.2. Clinical and Histological Data
2.3. Statistical Analysis
3. Results
3.1. Correlations of Urine Nephrin and Podocalyxin with Histological Parameters
3.1.1. Light Microscopy
3.2. Electron Microscopy
4. Discussion
5. Conclusions
Disclosures
Funding
| HISTOLOGICAL PARAMETERS. | VALID | N=37 (%) |
| TUBULAR ATROPHY | 0% | 10.8 |
| <25% | 43.2 | |
| 25-50% | 27.0 | |
| >50% | 18.9 | |
| HYALINOSIS | ABSENT | 51.4 |
| 1 SEGMENTAL | 10.8 | |
| >1 SEGMENTAL | 16.2 | |
| 1 GLOBAL | 21.6 | |
| ARTHRIOSCLEROSIS | 0% | 13.5 |
| 1-25% | 32.4 | |
| 26-50% | 24.3 | |
| >50% | 29.7 | |
| INERSTITIAL INFLAMMATION | ABSENT | 37.8 |
| MILD | 16.2 | |
| MODERATE | 27.0 | |
| SEVERE | 18.9 | |
| INTESTITIAL FIBROSIS | <5% | 10.8 |
| <25% | 35.1 | |
| 26-50% | 35.1 | |
| >50% | 18.9 | |
| GLOBAL FUSION | NO | 70.3 |
| YES | 29.7 | |
| SEGMENTAL FUSION | NO | 29.7 |
| YES | 70.3 | |
| PODOCYTE SWELLING | YES | 100 |
| MICROCYSTIC PODOCYTE DEGENARATION | NO | 2.7 |
| YES | 97.3 | |
| AUTOPHAGIC BODIES | NO | 70.3 |
| YES | 29.7 | |
| DENSE DEPOSITS | NONE | 51.4 |
| MINOR | 24.3 | |
| MAJOR | 24.3 | |
| FIBRILS | NO | 91.9 |
| YES | 8.1 | |
| GB MEMBRANE THICKENING | NO | 8.1 |
| SEGMENTAL | 54.1 | |
| GLOBAL | 37.8 | |
| MICROVILLUS TRANSFORMATION | NO | 43.2 |
| YES | 56.8 |
References
- Wetmore JB, Guo H, Liu J, Collins AJ, Gilbertson DT. The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis. Kidney Int. 2016 Oct;90(4):853-60. Epub 2016 Jul 15. [CrossRef] [PubMed]
- Couser WG. Pathogenesis and treatment of glomerulonephritis-an update. J Bras Nefrol. 2016 Mar;38(1):107-22. English, Portuguese. [CrossRef] [PubMed]
- Nagata M. Podocyte injury and its consequences. Kidney Int. 2016 Jun;89(6):1221-30. Epub 2016 Mar 19. [CrossRef] [PubMed]
- Asanuma K. [The role of podocyte injury in chronic kidney disease]. Nihon Rinsho Meneki Gakkai Kaishi. 2015;38(1):26-36. Japanese. [CrossRef] [PubMed]
- Kielkopf CL, Bauer W, Urbatsch IL. Bradford Assay for Determining Protein Concentration. Cold Spring Harb Protoc. 2020 Apr 1;2020(4):102269. [CrossRef] [PubMed]
- Toora BD, Rajagopal G. Measurement of creatinine by Jaffe's reaction--determination of concentration of sodium hydroxide required for maximum color development in standard, urine and protein free filtrate of serum. Indian J Exp Biol. 2002 Mar;40(3):352-4. [PubMed]
- Roufosse C, Simmonds N, Clahsen-van Groningen M, Haas M, Henriksen KJ, Horsfield C, Loupy A, Mengel M, Perkowska-Ptasińska A, Rabant M, Racusen LC, Solez K, Becker JU. A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology. Transplantation. 2018 Nov;102(11):1795-1814. Erratum in: Transplantation. 2018 Dec;102(12):e497. Erratum in: Transplantation. 2022 Dec 1;106(12):e528. PMID: 30028786; PMCID: PMC7597974. [CrossRef] [PubMed Central]
- Sanjeev Sethi, Fernando C Fervenza, Standardized classification and reporting of glomerulonephritis, Nephrology Dialysis Transplantation, Volume 34, Issue 2, February 2019, Pages 193–199. [CrossRef]
- Grosch S, Erpicum P, Bouquegneau A, Jouret F, Bovy C. Le glomérule dans tous ses états [The glomerulus in all its states]. Rev Med Liege. 2022 May;77(5-6):330-337. French. [PubMed]
- Akankwasa G, Jianhua L, Guixue C, Changjuan A, Xiaosong Q. Urine markers of podocyte dysfunction: a review of podocalyxin and nephrin in selected glomerular diseases. Biomark Med. 2018 Aug;12(8):927-935. Epub 2018 Jul 6. [CrossRef] [PubMed]
- Kriz W. Podocyte is the major culprit accounting for the progression of chronic renal disease. Microsc Res Tech. 2002 May 15;57(4):189-95. [CrossRef] [PubMed]
- Kriz W, Shirato I, Nagata M, LeHir M, Lemley KV. The podocyte's response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol. 2013 Feb 15;304(4):F333-47. Epub 2012 Dec 12. [CrossRef] [PubMed]
- Asao R, Asanuma K, Kodama F, Akiba-Takagi M, Nagai-Hosoe Y, Seki T, Takeda Y, Ohsawa I, Mano S, Matsuoka K, Kurosawa H, Ogasawara S, Hirayama Y, Sekine S, Horikoshi S, Hara M, Tomino Y. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol. 2012 Sep;7(9):1385-93. Epub 2012 Jun 14. [CrossRef] [PubMed] [PubMed Central]
- Imaizumi T, Nakatochi M, Akiyama S, Yamaguchi M, Kurosawa H, Hirayama Y, Katsuno T, Tsuboi N, Hara M, Maruyama S. Urinary Podocalyxin as a Biomarker to Diagnose Membranous Nephropathy. PLoS One. 2016 Sep 26;11(9):e0163507. [CrossRef] [PubMed] [PubMed Central]
- Ahmed T. Abou Ghanima, Mohammed F. Almaghraby, Hossam M. Elsaadany, Mohammed A. Hosny, Roobina K. Kumar,Urinary podocalyxin and nephrin levels as biomarkers in lupus nephritis patients: Relation to renal involvement and disease activity,The Egyptian Rheumatologist,Volume 38, Issue 3,2016.
- Zeng L, Fung WW, Chan GC, Ng JK, Chow KM, Szeto CC. Urinary and Kidney Podocalyxin and Podocin Levels in Diabetic Kidney Disease: A Kidney Biopsy Study. Kidney Med. 2022 Nov 14;5(1):100569. [CrossRef] [PubMed] [PubMed Central]
- Kandasamy Y, Smith R, Lumbers ER, Rudd D. Nephrin - a biomarker of early glomerular injury. Biomark Res. 2014 Nov 23;2:21. [CrossRef] [PubMed] [PubMed Central]
- Ganesh, V., Murugan, M., Goud, V. G., & Gangannagari, V. K. (2022). Correlation of urinary nephrin with albubinuria to predict early onset of nephropathy in patients with type 2 diabetes mellitus. International Journal of Health Sciences, 6(S3), 4621–4630.
- Irena Kostovska , Katerina Tosheska Trajkovska, Svetlana Cekovska , Goce Spasovski ,Danica Labudovic Nephrin and Podocalyxin - New Podocyte Proteins for Early Detection of Secondary Nephropathies ,BANTAO Journal,2016.
- Sekulic, Miroslav, and Simona Pichler Sekulic. "A compendium of urinary biomarkers indicative of glomerular podocytopathy." Pathology research international 2013 (2013).
- Abou Ghanima, Ahmed T., et al. "Urinary podocalyxin and nephrin levels as biomarkers in lupus nephritis patients: Relation to renal involvement and disease activity." The Egyptian Rheumatologist 38.3 (2016): 177-182.
- Inoue, K. Inoue K. Urinary Podocyte Biomarkers and Glomerular Histologic Change. Kidney360. 2022 Jan 20;3(3):407-409. [CrossRef] [PubMed] [PubMed Central]
- Hara M, Yamagata K, Tomino Y, Saito A, Hirayama Y, Ogasawara S, Kurosawa H, Sekine S, Yan K. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia. 2012 Nov;55(11):2913-9. Epub 2012 Aug 2. [CrossRef] [PubMed] [PubMed Central]
- Petrica L, Ursoniu S, Gadalean F, Vlad A, Gluhovschi G, Dumitrascu V, Vlad D, Gluhovschi C, Velciov S, Bob F, Matusz P, Milas O, Secara A, Simulescu A, Popescu R. Urinary podocyte-associated mRNA levels correlate with proximal tubule dysfunction in early diabetic nephropathy of type 2 diabetes mellitus. Diabetol Metab Syndr. 2017 May 6;9:31. [CrossRef] [PubMed] [PubMed Central]
| Variable | Healthy controls N=5 | Mean±SD N=37 |
|---|---|---|
| Age, y | 39±5 | 58 ±15 |
| Females, % | 3 (60) | 13 (35) |
| Positive urine sediment, % | 0 | 21 (56) |
| Nephrotic range proteinuria, % | 0 | 17 (45) |
| Hypertension, % | 0 | 20 (54) |
| Diabetes mellitus, % | 0 | 10 (27) |
| Serum creatinine, mg/dl | 0.8±0.3 | 2.2±1.8 |
| Proteinuria, gr/24h | 0 | 4.1±3.4 |
| Nephrin, ng/ml | 25.3±1.3 | 45.4±31.7 |
| Podocalyxin, ng/ml | 30.8±6.2 | 70.9±63 |
| NEP/CR , ng/mg | 0.22±0.2 | 1.05±0.99 |
| PDC/CR, ng/mg | 0.33±0.4 | 1.84±2 |
| Diagnosis | N |
|---|---|
| FSGS (primary/secondary/ tip lesion) | 4/8/1 |
| Alport syndrome | 1 |
| IgA nephropathy | 5 |
| IgG4 related GN | 2 |
| MCD | 1 |
| MIDD | 1 |
| Hypertensive nephropathy | 2 |
| Pauci-immune GN | 3 |
| Diabetic nephropathy | 1 |
| Membranous GN | 2 |
| SLE | 2 |
| TMA | 3 |
| Crescentic GN | 1 |
| a). | |||||||
| NEP/CR | Coef. | SE | t-value | p-value | [95% Conf. Interval] | ||
| Tubular Atrophy >50% | 1.272 | 0.36 | 3.53 | 0.001 | 0.54 to 2.003 | ||
| Intestitial Fibrosis >50% | 1.425 | 0.343 | 4.15 | <0.001 | 0.728 to 2.122 | ||
| Interstitial inflammation>25% | 0.673 | 0.291 | 2.31 | 0.028 | 0.076 to 1.27 | ||
| Segmental podocyte foot processes fusion | -0.702 | 0.274 | -2.56 | 0.016 | -1.264 to -.141 | ||
| b). | |||||||
| PDC/CR | Coef. | SE | t-value | p-value | [95% Conf. Interval] | ||
| Tubular Atrophy >50% | 2.721 | 0.725 | 3.75 | 0.001 | 1.248 to 4.193 | ||
| Interstitial fibrosis >50% | 2.603 | 0.738 | 3.53 | 0.001 | 1.106 to 4.1 | ||
| Arterial Hyalinosis | 1.906 | 0.751 | 2.54 | 0.016 | 0.382 to 3.43 | ||
| Interstitial inflammation >25% | 1.55 | 0.622 | 2.49 | 0.018 | 0.287 to 2.813 | ||
| Variable | Coef. | SE | t-value | p-value | [95% Conf. Interval] |
|---|---|---|---|---|---|
| Segmental glomerulosclerosis | 1.778 | 0.951 | 1.87 | 0.071 | -0.162 to 3.718 |
| Normotension | -0.14 | 0.293 | -0.48 | 0.636 | -0.738 to 0.458 |
| Interstitial inflammation >25% | 0.796 | 0.26 | 3.06 | 0.005 | 0.266 to 1.327 |
| Segmental fusion | -0.718 | 0.282 | -2.54 | 0.016 | -1.293 to -0.142 |
| Immune-complex mediated GN | -0.493 | 0.291 | -1.70 | 0.1 | -1.087 to 0.1 |
| Constant | 1.156 | 0.349 | 3.31 | 0.002 | 0.444 to 1.868 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).